Clinical Trial Update: A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

A Phase 2 randomized study evaluating two enoxaparin sodium doses in combination with standard chemotherapy for stage small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Lovenox (enoxaparin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN